Janssen’s Invokana reduces cardiovascular risk in diabetes patients

This article was originally published here

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced results of a new analysis showing that Invokana (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply